May 11, 2020 / 10:54 PM / a month ago

BRIEF-Halozyme Reports Q1 Loss Per Share $0.04

May 11 (Reuters) - Halozyme Therapeutics Inc:

* Q1 REVENUE ESTIMATE $43 MILLION — REFINITIV IBES DATA

* Q1 EARNINGS PER SHARE ESTIMATE $-0.02 — REFINITIV IBES DATA

* 2020 GUIDANCE OF $0.60 TO $0.75 EARNINGS PER SHARE WITH PROFITABILITY BEGINNING Q2 REMAINS UNCHANGED

* HALOZYME THERAPEUTICS - BLA ACCEPTED FOR SUBCUTANEOUS FIXED-DOSE COMBINATION OF PERJETA, HERCEPTIN UTILIZING ENHANZE WITH FDA ACTION DATE OF OCT 18

* POSITIVE CHMP OPINION RECOMMENDING APPROVAL OF DARZALEX® SC FORMULATION IN MULTIPLE CURRENT IV DARZALEX INDICATIONS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below